Navigation Links
Discovering a 'THRIL' that correlates with severity of Kawasaki disease
Date:12/26/2013

LA JOLLA, Calif., December 26, 2013 Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cellsmacrophagesare stimulated in response to pathogens. The molecule, termed "THRIL," helps regulate the immune response and shows an association with Kawasaki disease. The findings suggest that THRIL may contribute to other inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The study, published online in Proceedings of the National Academy of Sciences, measured large intergenic noncoding RNA (lincRNA) produced when the immune system is activated. One lincRNA was found to bind heterogenous nuclear ribonucleoprotein L (hnRNPL), creating a new molecule that regulates genetic control of TNF-alphaa potent cytokine that promotes inflammation. The authors named the molecule THRIL, after TNF-alpha and hnRNPL-related immunoregulatory lincRNA.

Noncoding RNAs as key regulators of immune response

Large noncoding RNA corresponds to the parts of the genome that do not code for protein.

"For some time we have known that noncoding regions of RNA play important roles in regulating the immune response to microbial pathogens," said Tariq Rana, Ph.D., senior author of the study and professor in the Sanford Children's Health Research Center and director of the RNA Biology Program at Sanford-Burnham. "When we realized that THRIL functioned to control the TNF-alpha gene, we wanted to see if it mirrors the progression in inflammatory diseases."

Collaborating with Jane Burns, M.D., professor of pediatrics at Rady Children's Hospital and UC San Diego, Rana's team measured THRIL levels in Kawasaki disease samples at different stages of the disease, and found that levels were at their lowest during the acute stage of the diseasewhen TNF-alpha levels are at their highest.

The findings suggest that THRIL could be a novel biomarker for immune activation and a potential target for inflammatory diseases.


'/>"/>

Contact: Susan Gammon
858-795-5012
Sanford-Burnham Medical Research Institute
Source:Eurekalert  

Related biology news :

1. The next era in discovering drugs in natures own medicine cabinet
2. Researchers develop tools for discovering new species
3. Discovering cell surface proteins behavior
4. Protein explains increased asthma severity in children exposed to diesel exhaust from traffic
5. Small protein plays big role in asthma severity
6. Probiotic bacterium lessens severity of Salmonella infections by hoarding iron
7. CSHL geneticists solve mystery of EEC Syndromes variable severity in children
8. Gut microbes could determine the severity of melamine-induced kidney disease
9. Researchers show prebiotic can reduce severity of colitis
10. Exposure to antibiotics linked to severity of allergic asthma: UBC research
11. Gene therapy for human skin disease produces long-term benefits
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovering a 'THRIL' that correlates with severity of Kawasaki disease
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
(Date:2/3/2016)... Ascendis Pharma A/S (Nasdaq: ASND ), ... TransCon technology to address significant unmet medical needs, today ... Leerink Partners Global Healthcare Conference Location: , Waldorf ... 2016 Time:  , 11:55am EST www.ascendispharma.com ... An audio webcast of this event will be posted ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
Breaking Biology Technology: